Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Osimertinib"

Approximately 10% of EGFR mutants harbor uncommon mutations, which represent a heterogeneous group of rare molecular alterations within exons 18-21 and the sensitivity to EGFR tyrosine kinase inhibito ...

Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free survival ( DFS ) in patients with epidermal growth factor receptor-muta ...